United Therapeutics: all 103 studies

Page 1 of 2. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRDRecruitingNCT07224763Phase 1/2
• Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRDRecruitingNCT06878560Phase 1/2
• DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)RecruitingNCT06388421
• Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)RecruitingNCT05943535Phase 3
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseEnrolling by invitationNCT04905693Phase 3
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionEnrolling by invitationNCT03683186Phase 3
• Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedNCT05255991Phase 3Results posted
• Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsTerminatedNCT04084678Phase 3Results posted
• Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using TyvasoCompletedNCT03950739Phase 1Results posted
• Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAHCompletedNCT03888365Results posted
• A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPDTerminatedNCT03857841Phase 1Results posted
• Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)TerminatedNCT03794583Phase 3Results posted
• Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESHCompletedNCT03735862Results posted
• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial HypertensionTerminatedNCT03657095Phase 3Results posted
• Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP FacilityCompletedNCT03641677Not applicableResults posted
• EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial HypertensionCompletedNCT03497689Phase 4Results posted
• A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT03496623Phase 3Results posted
• MIRODERM H2H DFU StudyCompletedNCT03232333Results posted
• Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerCompletedNCT03098030Phase 2/3Results posted
• TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)CompletedNCT03055221Phase 4Results posted
• Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFTerminatedNCT03043651Phase 3Results posted
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionTerminatedNCT03037580Phase 3Results posted
• Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)CompletedNCT02847260Phase 4Results posted
• Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma PatientsTerminatedNCT02693171Results posted
• An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFETerminatedNCT02633293Phase 2/3Results posted
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFECompletedNCT02630316Phase 2/3Results posted
• Miromatrix Biological Mesh for Hiatal Hernia RepairCompletedNCT02436681Not applicableResults posted
• Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial HypertensionCompletedNCT02279745Phase 2Results posted
• Safety and Efficacy of APD811 in Pulmonary Arterial HypertensionCompletedNCT02279160Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 YearsCompletedNCT02276872Phase 2Results posted
• Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the NewbornTerminatedNCT02261883Phase 2Results posted
• Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP FacilityCompletedNCT02234128Not applicableResults posted
• A Pharmacokinetic Substudy of the TDE-PH-304 ProtocolCompletedNCT01934582Phase 3Results posted
• Beraprost-314d Added-on to Tyvaso® (BEAT)CompletedNCT01908699Phase 3Results posted
• ch14.18 Pharmacokinetic Study in High-risk NeuroblastomaCompletedNCT01592045Phase 1/2Results posted
• Remodulin® to Oral Treprostinil TransitionCompletedNCT01588405Phase 2Results posted
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionCompletedNCT01560637Phase 3Results posted
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyCompletedNCT01560624Phase 3Results posted
• Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®CompletedNCT01477333Phase 2Results posted
• Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH TherapiesCompletedNCT01266265Results posted
• A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary HypertensionCompletedNCT01104870Phase 2Results posted
• A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary HypertensionCompletedNCT01028651Results posted
• An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionCompletedNCT01027949Phase 3Results posted
• Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT00990314Phase 2Results posted
• Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT00989963Phase 2Results posted
• Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial HypertensionCompletedNCT00887978Phase 3Results posted
• Open-Label Study of Oral Treprostinil in Digital UlcersTerminatedNCT00848107Phase 2Results posted
• An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT00792571Phase 2Results posted
• A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH PatientsCompletedNCT00781885Phase 2Results posted
• Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineCompletedNCT00775463Phase 2Results posted
• Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) SubjectsCompletedNCT00741819Phase 4Results posted
• Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00703339Phase 2Results posted
• Rapid Switch From Flolan to Remodulin in the Outpatient ClinicTerminatedNCT00643604Phase 4Results posted
• Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAHTerminatedNCT00439946Phase 4Results posted
• Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to RemodulinCompletedNCT00373360Phase 4Results posted
• FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT00325442Phase 3Results posted
• FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT00325403Phase 3Results posted
• Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)CompletedNCT00147199Phase 3Results posted
• miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 TrialCompletedNCT06285253Phase 1
• Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier DetectionCompletedNCT05776225
• A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionActive, not recruitingNCT05203510Phase 4
• Evaluate Real-World Use of Next Generation Infusion Pumps to Administer RemodulinTerminatedNCT05060315
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisCompletedNCT04708782Phase 3
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsCompletedNCT03626688Phase 3
• Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)WithdrawnNCT03055234Phase 3
• ADAPT - A Patient Registry of the Real-world Use of Orenitram®Active, not recruitingNCT03045029
• Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAHWithdrawnNCT03016468Phase 2
• Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPDWithdrawnNCT03012646Phase 2
• Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial HypertensionWithdrawnNCT02999906Phase 3
• Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial HypertensionWithdrawnNCT02893995Phase 4
• An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial HypertensionWithdrawnNCT02882126Phase 4
• MIRODERM™ for Complex Wounds in an Inpatient Setting (MIRODERM CLOSure)WithdrawnNCT02732548Not applicable
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary FibrosisWithdrawnNCT02603068Phase 2
• Miromatrix Biological Mesh for Ventral Hernia RepairWithdrawnNCT02408458Not applicable
• Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy VolunteersCompletedNCT02318758Phase 1
• Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male VolunteersWithdrawnNCT02149095Phase 1
• Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant RecipientsWithdrawnNCT01884038Phase 2/3
• Tyvaso Dosing and Titration Evaluation: TyTRATE RegistryCompletedNCT01799473
• Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)TerminatedNCT01795950Phase 1
• Three Times Daily Dosing of UT-15CCompletedNCT01746485Phase 1
• Inhaled Treprostinil for PAH: Open-label ExtensionWithdrawnNCT01557660Phase 3
• Safety and Efficacy of Inhaled Treprostinil in Patients With PAHWithdrawnNCT01557647Phase 3
• A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 InhibitorWithdrawnNCT01458236Phase 3
• A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy VolunteersCompletedNCT01172496Phase 1
• Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent FacilitiesCompletedNCT01165476Phase 1
• Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil DiethanolamineCompletedNCT01153386Phase 1
• The Effect of Renal Impairment on the Pharmacokinetics of Oral TreprostinilCompletedNCT01131845Phase 1
• A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma PatientsTerminatedNCT00969722Phase 2
• Effect of Esomeprazole on the Pharmacokinetics of Oral TreprostinilCompletedNCT00963027Phase 1
• Effect of Food on the Pharmacokinetics of Oral TreprostinilCompletedNCT00963001Phase 1
• Pharmacokinetics of Oral Treprostinil in Patients With Systemic SclerosisCompletedNCT00848939Phase 1
• FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)WithdrawnNCT00760916Phase 3
• Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial HypertensionTerminatedNCT00494533Phase 4
• Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment SatisfactionTerminatedNCT00458042Phase 4
• Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer TreatmentTerminatedNCT00086632Phase 2
• 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.Status unknownNCT00069511Phase 2
• Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass GraftTerminatedNCT00067041Phase 2/3
• Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization ProceduresTerminatedNCT00060996Phase 3
• A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial HypertensionCompletedNCT00058929Phase 4
• Clinical Trial for Ovarian Cancer (OvaRex®)TerminatedNCT00050375Phase 3

← United Therapeutics overview and focus areas